Table 6.
Multivariate analysis
| Factor | PFS |
OS |
|||
|---|---|---|---|---|---|
| Hazard ratio | p value | Hazard ratio | p value | ||
| CEA (<7.0 mg/ml vs ≧7.0 mg/ml) | 0.29 (0.07–1.29) | 0.11 | |||
| Treg (≧26.2/mm3 vs <26.2/mm3) | 1.22 (0.20–7.49) | 0.83 | 1.15 (0.31–4.19) | 0.84 | |
| mGPS (1.2 vs 0) | 0.27 (0.03–2.46) | 0.25 | 3.04 (0.47–19.59) | 0.24 | |
| NLR (<5 vs ≧5) | 0.24 (0.05–1.27) | 0.093 | 0.60 (0.14–2.45) | 0.47 | |
| PNI (<40 vs ≧40) | 3.24 (0.20–51.25) | 0.4 | 0.36 (0.04–2.98) | 0.34 | |
| MUC1 ELIspot (<12.8 vs≧12,8) | 23.68 (1.99–282.00) | 0.012* | 19.26 (1.81–204.90) | 0.014* | |
| WT1 ELIspot (<9.3 vs ≧9.3) | 0.51 (0.04–6.10) | 0.6 | 6.11 (1.11–33.79) | 0.038* | |
| Skin reaction (<30 mm vs ≧30 mm) | 4.91 (0.23–102.80) | 0.3 | 4.43 (0.89–22.13) | 0.07 | |
Two groups in the CEA, Treg, MUC1 ELIspot and WT1 ELIspot were divided by the median value. The cutoff values for the mGPS, NLR, PNI and skin reaction are determined on the basis of previous studies.17,28,29,32,33 Parenthesis represents a 95% confidence interval. PFS, progression free survival; OS, overall survival; CEA, carcinoembryonic antigen; Treg, regulatory T cell; mGPS, modified Glasgow prognostic score; NLR, neutrophil to lymphocyte ratio; PNI, prognostic nutritional index; MUC1, Mucin1; WT1, Wilms’ tumor 1; ELIspot, enzyme-linked immunospot. *represents statistically significant.